Greenhaven Road Investment Management, LP on Cellebrite DI Ltd.
Thesis
The market increasingly treats Cellebrite as vulnerable to AI disruption, while Greenhaven believes AI can expand the company's opportunity. Cellebrite's Genesis product embeds its specialized digital-forensics expertise into an AI workflow and management believes the product could double the addressable market. Company guidance and consensus estimates assume essentially no Genesis revenue, creating upside if initial adoption converts into meaningful consumption-based sales. Registered users increased rapidly during the beta and early launch period, and the company continues to combine strong recurring growth, cash generation and a solid balance sheet with a relatively modest valuation.
“Our non-consensus view is that AI will ultimately benefit Cellebrite.”
Key risks
- Genesis may fail to generate meaningful commercial adoption
- AI or technological changes could disrupt existing digital-forensics workflows
- The market may continue assigning a lower multiple to the business